CRDF (Cardiff Oncology) Other Current Receivables: $0.00 Mil (As of Mar. 2026)


CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $1.32
GF Value $1.42
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Other Current Receivables?

Cardiff Oncology CRDF +4.35% 48 Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.42 (Fairly Valued). The stock has 4 warning signs investors should review.

Cardiff Oncology's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Cardiff Oncology Other Current Receivables Related Terms

Cardiff Oncology Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Other Current Receivables Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CRDF
48GF Score
Cardiff Oncology Inc CRDF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Cardiff Oncology (CRDF) has a Other Current Receivables of $0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Other Current Receivables too high?
Cardiff Oncology's current Other Current Receivables is $0.00 Mil. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Other Current Receivables compare to MAIA and TELO?
Cardiff Oncology's Other Current Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Fairly Valued. The stock's GF Value™ is $1.42, compared to a current price of $1.32 — trading 7% below its estimated fair value. The current Other Current Receivables is $0.00 Mil. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.32 is trading 7% below its estimated GF Value™ of $1.42. GuruFocus considers Cardiff Oncology to be Fairly Valued.

Key valuation signals for CRDF:

  • Other Current Receivables: $0.00 Mil
  • GF Value™: $1.42 vs. price of $1.32 (7% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price
$1.42
GF Value